Denville Partners (@PartnerInSearch) header
Denville Partners (@PartnerInSearch) profile picture

Executive Search: Biotech, Pharma, MedTech and related nonprofits. We help drive drug development and build mission driven teams. Rare & common disorders.

Boston
Joined November 2013
Photo by Denville Partners (@PartnerInSearch)Photo by Denville Partners (@PartnerInSearch)Photo by Denville Partners (@PartnerInSearch)Photo by Denville Partners (@PartnerInSearch)Photo by Denville Partners (@PartnerInSearch)Photo by Denville Partners (@PartnerInSearch)Photo by Denville Partners (@PartnerInSearch)Photo by Denville Partners (@PartnerInSearch)Photo by Denville Partners (@PartnerInSearch)Photo by Denville Partners (@PartnerInSearch)
Denville Partners retweeted
Q4 and early 2027 hiring continues year-round. Search firms bring comp insight, protect confidentiality, maintain momentum, and negotiate Q1 bonuses, buyouts & equity. Partners through the calendar, not just CVs. #Hiring
1
1
29
Denville Partners retweeted
Current open non-profit opportunities: VP of Corporate Development and Innovation (ALS) CEO - rare and ultra rare diseases COO - rare diseases, operational and finance We are Denville Partners working at the nexus of nonprofit impact and biotech innovation.
1
1
1
27
Denville Partners retweeted
Nonprofit CEOs and EDs must lead technology, not just manage it. AI, data and digital fundraising can amplify mission and unlock growth. The wrong hire can cost millions. #ExecutiveSearch #NonprofitLeadership
1
1
17
Denville Partners retweeted
Succession is an opportunity to hire for the future: not replace the past. Seek leaders who scale impact, embrace technology, and build partnerships that move the mission forward. #NonprofitLeadership #SuccessionPlanning
1
1
31
Denville Partners retweeted
Throughout her career caring for children and developing medicines for rare diseases, Nerissa Kreher has met many families searching for a treatment option for their child or loved one. For many rare and ultra-rare diseases, small patient populations can make studying each disease separately difficult. Basket trials offer another potential path, bringing together people with different diseases that share the same underlying mutation and relevant clinical characteristics. On Labiotech’s Beyond Biotech podcast, Nerissa discusses why engineered tRNA medicines may be well suited to this approach, the clinical development of AP003, the first tRNA therapeutic to enter clinical trials, and the evidence needed to support future basket trials. Listen here: podcast.labiotech.eu/1995493…
1
4
198
Denville Partners retweeted
Sometimes a nonprofit’s most promising program belongs outside it. A dedicated spin-out can bring focused capital, speed, and risk tolerance: while the nonprofit retains equity, a seat at the table, and the upside.
1
3
36
Denville Partners retweeted
Today, we announced our Q2 2026 financial results and corporate highlights. Read more in our press release: bit.ly/4zf5dJ0
1
1
144
Denville Partners retweeted
ALS-TDI’s patient-driven model connects patient data, iPSC models and drug discovery. Its copper-complex lead, TDI-1831, is advancing through IND-enabling studies. #ALSResearch #RareDisease
1
1
65
Denville Partners retweeted
What if the money for research reached scientists in weeks instead of years? American scientists now spend nearly half their time on paperwork. Some grants take two years to approve. The White House just called this out and asked for the biggest rebuild of science since 1945. It wants funding to reach researchers directly, young scientists backed early, and people judged on their work, not their place in line. It also says AI will change how discovery happens, but the best models will stall inside institutions built for the last century. This is the model onchain science already runs. A scientist with an agent fleet and an onchain treasury can run programs that once needed a whole institution. The funding comes straight from the people who want the work done. Every step is recorded in the open. The scientist sets the direction, and the infrastructure carries it out. The report is describing a future we are already building at Bio.
13
16
2
118
8,780
Denville Partners retweeted
Call for Research Proposals! Each year, the ULF welcomes researchers from around the world to submit their research project proposals for funding consideration. Applications are now being accepted through August 12, 2026. For more details, visit: ulf.org/research/research-gr…
1
1
16
Denville Partners retweeted
Excited to kick off our #CAMP4Fireside Series to highlight the people behind CAMP4. Hear from our CEO, Josh Mandel-Brehm, as he shares a glimpse into what’s ahead. Watch the video, and learn more about our mission here: camp4tx.com/
1
2
84
Denville Partners retweeted
Biotech startups offer a 'resilience dividend.' Even if a venture fails, the experience of building from scratch is resume gold. These unique skills make it a low-risk career move in the long run. #BiotechCareers #Resilience #DenvillePartners #Leadership
1
2
22
Columnist Patrick Moeschen invites readers to join the newly relaunched Muscular Dystrophy News Today Forums, where a community is growing. buff.ly/FyFBeli #musculardystrophynews #musculardystrophy #musculardystrophycommunity #livingwithMD
2
6
124
Denville Partners retweeted
Today we announced our Q1 2026 financial results highlighting progress across our pipeline. See the press release here bit.ly/3RxC4Y5
2
5
399
Denville Partners retweeted
Registration is now open for the ULF Scientific Symposium & Family Conference June 25-27 at Hilton Chicago/Oak Brook Hills Resort & Conference Center, Oak Brook, IL 60523. Take advantage of discounted early bird rates by registering by 3/13/26. Register bit.ly/4qUrYh0
2
1
29
Denville Partners retweeted
Kicking off our new Scientific Shorts series: a new series designed to break down big ideas in endocrinology. First up: What is the endocrine system? Watch Crinetics Chief Endocrinologist, Alan Krasner, M.D., explain how the endocrine system plays a critical role in everyday health and helps keep the body in balance.
1
1
6
2,125
Denville Partners retweeted
Our potentially disease modifying therapy for myotonic dystrophy type 1, PGN-EDODM1, is being evaluated in the phase 2 FREEDOM2-DM1 clinical study. Learn more in the video below.
2
4
227
Denville Partners retweeted
At the @jpmorgan Healthcare Conference, we’ll share how our clinically validated FORCE™ platform is advancing therapies designed to deliver functional improvement for genetically driven neuromuscular diseases. Learn more: bit.ly/3zHnp4e $DYN #JPM26 #JPM2026
2
6
511
Denville Partners retweeted
This week, Chief Medical Officer, Gabriel Brooks, M.D., and Head of Discovery and Translational Development, Nicolas Christoforou, Ph.D., will be showcasing data from our proprietary next-generation capsid, AAV-SLB101, and our cardiac gene therapy pipeline at the @CVCTForum in Washington, D.C. Read the full release for details on our poster, oral presentations, and panel discussions: investors.solidbio.com/news-… $SLDB
1
5
291
Denville Partners retweeted
Huge competitive advantage for our firm. We have an incredibly unique seat in the biotech / pharma world.
Nonprofit experience arms biotech/pharma execs with rare mission-driven perspective and strategic leadership skills. That edge isn’t talked about enough: transforming not just teams, but outcomes. @DenvillePartners #Leadership #Biotech #Csuite #MissionDriven
1
1
53